BACKGROUND: Cannabis is one of the most widely used illicit substances, and there is growing interest in the therapeutic applications of cannabinoids. While known to modulate neuroendocrine function, the precise acute and chronic dose-related effects of cannabinoids in humans are not well-known. Furthermore, the existing literature on the neuroendocrine effects of cannabinoids is limited by small sample sizes (n = 6-22), heterogeneous samples with regard to cannabis exposure (lumping users and nonusers), lack of controlling for chronic cannabis exposure, differing methodologies, and limited dose-response data. Delta-9-tetrahydrocannabinol (Delta-9-THC) was hypothesized to produce dose-related increases in plasma cortisol levels and decreases in plasma prolactin levels. Furthermore, relative to controls, frequent users of cannabis were hypothesized to show altered baseline levels of these hormones and blunted Delta-9-THC-induced changes of these hormones. MATERIALS AND METHODS: Pooled data from a series of laboratory studies with multiple doses of intravenous Delta-9-THC in healthy control subjects (n = 36) and frequent users of cannabis (n = 40) was examined to characterize the acute, chronic, and acute on chronic effects of cannabinoids on plasma cortisol and prolactin levels. Hormone levels were measured before (baseline) and 70 min after administration of each dose of Delta-9-THC. Data were analyzed using linear mixed models with +70 min hormonal levels as the dependant variable and baseline hormonal level as the covariate. RESULTS: At socially relevant doses, Delta-9-THC raised plasma cortisol levels in a dose-dependent manner but frequent users showed blunted increases relative to healthy controls. Frequent users also had lower baseline plasma prolactin levels relative to healthy controls. CONCLUSIONS: These group differences may be related to the development of tolerance to the neuroendocrine effects of cannabinoids. Alternatively, these results may reflect inherent differences in neuroendocrine function in frequent users of cannabis and not a consequence of cannabis use.
BACKGROUND: Cannabis is one of the most widely used illicit substances, and there is growing interest in the therapeutic applications of cannabinoids. While known to modulate neuroendocrine function, the precise acute and chronic dose-related effects of cannabinoids in humans are not well-known. Furthermore, the existing literature on the neuroendocrine effects of cannabinoids is limited by small sample sizes (n = 6-22), heterogeneous samples with regard to cannabis exposure (lumping users and nonusers), lack of controlling for chronic cannabis exposure, differing methodologies, and limited dose-response data. Delta-9-tetrahydrocannabinol (Delta-9-THC) was hypothesized to produce dose-related increases in plasma cortisol levels and decreases in plasma prolactin levels. Furthermore, relative to controls, frequent users of cannabis were hypothesized to show altered baseline levels of these hormones and blunted Delta-9-THC-induced changes of these hormones. MATERIALS AND METHODS: Pooled data from a series of laboratory studies with multiple doses of intravenous Delta-9-THC in healthy control subjects (n = 36) and frequent users of cannabis (n = 40) was examined to characterize the acute, chronic, and acute on chronic effects of cannabinoids on plasma cortisol and prolactin levels. Hormone levels were measured before (baseline) and 70 min after administration of each dose of Delta-9-THC. Data were analyzed using linear mixed models with +70 min hormonal levels as the dependant variable and baseline hormonal level as the covariate. RESULTS: At socially relevant doses, Delta-9-THC raised plasma cortisol levels in a dose-dependent manner but frequent users showed blunted increases relative to healthy controls. Frequent users also had lower baseline plasma prolactin levels relative to healthy controls. CONCLUSIONS: These group differences may be related to the development of tolerance to the neuroendocrine effects of cannabinoids. Alternatively, these results may reflect inherent differences in neuroendocrine function in frequent users of cannabis and not a consequence of cannabis use.
Authors: F Rodríguez De Fonseca; M A Gorriti; A Bilbao; L Escuredo; L M García-Segura; D Piomelli; M Navarro Journal: Neurotox Res Date: 2001-01 Impact factor: 3.911
Authors: R Androvicova; J Horacek; J Tintera; J Hlinka; J Rydlo; D Jezova; M Balikova; T Hlozek; P Miksatkova; M Kuchar; M Roman; P Tomicek; F Tyls; M Viktorinova; T Palenicek Journal: Psychopharmacology (Berl) Date: 2017-04-12 Impact factor: 4.530
Authors: Lorenzo Somaini; Matteo Manfredini; Mario Amore; Amir Zaimovic; Maria Augusta Raggi; Claudio Leonardi; Maria Lidia Gerra; Claudia Donnini; Gilberto Gerra Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-07-20 Impact factor: 5.270
Authors: Carrie Cuttler; Alexander Spradlin; Amy T Nusbaum; Paul Whitney; John M Hinson; Ryan J McLaughlin Journal: Psychopharmacology (Berl) Date: 2017-05-31 Impact factor: 4.530
Authors: Mohini Ranganathan; Jose Cortes-Briones; Rajiv Radhakrishnan; Halle Thurnauer; Beata Planeta; Patrick Skosnik; Hong Gao; David Labaree; Alexander Neumeister; Brian Pittman; Toral Surti; Yiyun Huang; Richard E Carson; Deepak Cyril D'Souza Journal: Biol Psychiatry Date: 2015-08-29 Impact factor: 13.382